scholarly journals PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions

2015 ◽  
Vol 113 (S1) ◽  
pp. S10-S16 ◽  
Author(s):  
Jonathan A Ledermann ◽  
Fatima El-Khouly
Keyword(s):  
Ovarian Cancer ◽  
Clinical Evidence ◽  
Treatment Decisions ◽  
Parp Inhibitors ◽  
Informed Treatment

scholarly journals Latest clinical evidence and further development of PARP inhibitors in ovarian cancer

2018 ◽  
Vol 29 (6) ◽  
pp. 1366-1376 ◽  
Author(s):  
M.R. Mirza ◽  
S. Pignata ◽  
J.A. Ledermann
Keyword(s):  
Ovarian Cancer ◽  
Clinical Evidence ◽  
Parp Inhibitors ◽  
Further Development

scholarly journals Tumour Versus Germline BRCA Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom

Diagnostics ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 547
Author(s):  
Iolia Akaev ◽  
Siavash Rahimi ◽  
Olubukola Onifade ◽  
Francis John Edward Gardner ◽  
David Castells-Rufas ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Unknown Origin ◽  
Parp Inhibitors ◽  
Serous Carcinoma ◽  
High Grade ◽  
Brca1 And Brca2 ◽  
Brca Mutations ◽  
Epithelial Cancers ◽  
Pathogenic Variants ◽  
Pathogenic Mutations

The aim of this audit was to evaluate the usefulness and serviceability of testing for pathogenic mutations in BRCA1 or BRCA2 (BRCA1/2) genes in ovarian cancer (OC) patients. One hundred and thirty-five patients with more common histological sub-types of OC were retrospectively identified between 2011 and 2019. The fail rate of the molecular analysis was 7.4% (10/135). One hundred and twenty-five records were evaluated: 99 (79.2%) patients had wild-type BRCA (both somatic and germline); tumour BRCA1/2 (tBRCA1/2) pathogenic mutations were found in 20 (16%) patients with distribution between BRCA1 and BRCA2 being 40% and 60%, respectively; 13 (10.4%) patients with pathogenic variants had germline mutations; and tBRCA1/2 with variant of unknown significance (VUS), in the absence of pathogenic BRCA1 or BRCA2 variants, was detected in 6 (4.8%) patients. Our data show that expanding the molecular service to the routine first-tumour testing for patients with OC will potentially increase the detection rate of BRCA mutations, thereby providing early benefits of PARP inhibitors therapy. The tumour testing service should continue to be offered to newly diagnosed patients with high-grade epithelial cancers, including high-grade serous carcinoma, but also with carcinosarcomas and poorly-differentiated metastatic adenocarcinomas of unknown origin.

scholarly journals Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy

2021 ◽  
Vol 22 (8) ◽  
pp. 4203
Author(s):  
Giorgio Valabrega ◽  
Giulia Scotto ◽  
Valentina Tuninetti ◽  
Arianna Pani ◽  
Francesco Scaglione
Keyword(s):  
Ovarian Cancer ◽  
Signal Transduction ◽  
Dna Damage ◽  
Chemical Structure ◽  
Parp Inhibitors ◽  
Mechanisms Of Action ◽  
Point Of View ◽  
Safety And Efficacy ◽  
Damage Repair ◽  
Pharmacokinetic Properties

Poly(ADP-ribose) polymerases (PARP) are proteins responsible for DNA damage detection and signal transduction. PARP inhibitors (PARPi) are able to interact with the binding site for PARP cofactor (NAD+) and trapping PARP on the DNA. In this way, they inhibit single-strand DNA damage repair. These drugs have been approved in recent years for the treatment of ovarian cancer. Although they share some similarities, from the point of view of the chemical structure and pharmacodynamic, pharmacokinetic properties, these drugs also have some substantial differences. These differences may underlie the different safety profiles and activity of PARPi.

scholarly journals Treatment Decisions and Survival in Ovarian Cancer

2018 ◽  
Author(s):  
Hugo de Seabra Martins Nunes ◽  
Alexandra Mayer ◽  
Ana Francisca Jorge ◽  
Teresa Margarida Cunha ◽  
Ana Opinião ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Treatment Decisions

PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Peter G. Rose ◽  
Meng Yao ◽  
Laura M. Chambers ◽  
Haider Mahdi ◽  
Robert DeBernardo ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Parp Inhibitors ◽  
Platinum Based Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document